Skip to main content

What are monoclonal antibodies?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on June 3, 2025.

Official Answer by Drugs.com

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as certain cancers, rheumatoid arthritis or plaque psoriasis.

These advanced treatments are useful in treating cancer. Some monoclonal antibodies are targeted treatments and attack a very specific protein (antigens) on cancer cells. Others are considered immunotherapy because they help to boost our own immune system to find and attack cancers.

What are antibodies and antigens?

We have natural antibodies in our body. Antibodies are part of our immune system and seek out foreign substances (called antigens). Antibodies respond to antigens like viruses, bacteria, cancer cell proteins or other pathogens to mount an immune response and help kill them.

"Monoclonal" means that the antibody recognizes one specific antigen (protein) in the body. Some antibodies, called "polyclonal" antibodies, come from several different immune cells and recognize more than one type of antigen.

How do monoclonal antibodies work in cancer?

Monoclonal antibodies work in different ways in cancer treatment. Not all cancer cells are the same, and researchers have utilized these differences to enable specific treatments that act on those differences.

Monoclonal antibodies work by:

For example, targeted therapy works by interacting with specific targets (instead of affecting all cells) found in cancer. Immunotherapy treatments help to boost our own immune system to work better against cancers found in the body. Immune checkpoint inhibitors, like Keytruda (pembrolizumab) or Opdivo (nivolumab) are examples of this type of mAb.

Monoclonal antibody-based treatments are now considered a standard part of cancer therapy when needed, alongside other options, such as surgery, chemotherapy, hormone treatment or radiation therapy.

What types of monoclonal antibodies are there?

Monoclonal antibodies (mAbs) may be classified as either Naked, Conjugated or as Bispecific. They are usually made in the lab from mouse proteins, human proteins or a combination of the two.

Naked mAbs: The types of treatments are usually given alone and usually attach to antigens on cancer cells, but may attach to healthy cells or other proteins. They have no other components, like radioactive materials or medicines, attached to them.

Conjugated mAbs: These agents are combined with other drugs like chemotherapy (antibody-drug conjugates) or radioactive treatments. These tagged or labeled mABs help direct the treatment specifically to the cancer cells.

Bispecific mAbs: These medicines contain 2 mAbs which allow them to attach to 2 different proteins at the same time. These may also be called T-cell engagers (TCEs).

Classification of Monoclonal Antibodies

What diseases do monoclonal antibodies treat?

Some of the diseases that can be treated with monoclonal antibodies include:

Active research is ongoing to develop new medicines and find new uses for monoclonal antibodies. You may be eligible to join a clinical trial for treatment. Speak to your doctor about this option.

What are some examples of monoclonal antibodies?

Orthoclone OKT3 (muromonab-CD3) was the first licensed monoclonal antibody in the U.S. It gained clearance from the FDA in 1986 for use in preventing kidney transplant rejection. New monoclonal antibodies are constantly under research.

List of monoclonal antibodies and diseases they treat:

Related questions

More recent monoclonal antibodies approved by the FDA include:

Learn more: What is the mechanism of action (MOA) of Loqtorzi (toripalimab)?

*Note: This is not a complete list of all monoclonal antibodies available on the U.S. market or their indications. New drugs and uses are frequently approved by the FDA. If you have further questions about monoclonal antibodies you can search by name here and contact your healthcare provider.

How are monoclonal antibodies given?

These medicines are often injected into a vein (intravenously). You may receive this treatment at a special clinic called an infusion center. Your doctor will monitor you for any infusion or allergic reactions before you go home.

In some cases, monoclonal antibodies are injected subcutaneously (just under the skin) instead of into a vein.

Different drugs will have different schedules for administration based on your cancer type. Not all cancer regimens include monoclonal antibodies as part of the treatment plan.

Are biosimilars approved for monoclonal antibodies?

Biosimilars are increasingly being approved for many biologics, including monoclonal antibodies.

A biosimilar is not considered a “generic” in the same way that a traditional, small molecule drug (for example: ibuprofen or acetaminophen) is classified as a generic. As with generics, biosimilar cost savings for healthcare systems and the consumer are expected to be significant.

One example is Amjevita (adalimumab-atto), a tumor necrosis factor blocker and the first biosimilar approved for Humira. It is used for most of the same indications as Humira, including rheumatoid arthritis, Crohn's disease and psoriasis, but is not approved for uveitis. In this case, Humira is the reference product.

Learn more: What biosimilars have been approved in the United States?

What side effects occur with monoclonal antibodies?

A wide range of side effects can occur with monoclonal antibodies, depending upon your drug treatment and use. Some side effects can be very rare but can be serious or life-threatening, while other side effects may be common but not serious.

Talk with your healthcare provider about which side effects to expect from your treatment.

Common side effects

In general, common side effects with monoclonal antibodies can include:

Infusion reactions, which are more common when the drug is first being started, can include low blood pressure, fever, chills, skin rash, weakness, nausea/vomiting, headache, or diarrhea. Your doctor may give you medicine before your treatment to help prevent this side effect. Your cancer care team will watch you closely for this side effect.

Serious side effects

Serious, but less common, side effects may include:

To learn more about clinical trials through the National Cancer Institute, visit here.

This is not all the information you need to know about Monoclonal Antibodies for safe and effective use and does not take the place of your doctor’s directions. Review the full product information you receive about your medicine. Discuss this information and any questions you have with your doctor or other health care provider.

References

Read next

How long can you stay on Herceptin and Perjeta?

If you are receiving Perjeta for treatment of HER2+ early breast cancer, you may continue treatments with Herceptin every 3 weeks for one year (18 cycles total). For the treatment of HER2+ metastatic breast cancer, you will receive Perjeta and Herceptin until the medicine no longer controls your breast cancer or you have side effects that require you to stop treatment. You may receive other treatments with these medications. Continue reading

What happens after Herceptin treatment?

After Herceptin treatment, your doctor will monitor you regularly for cancer progression, advise you not to become pregnant for at least 7 months (if you are of childbearing potential), and test your heart every 6 months for at least 2 years, because there is a higher risk of developing long-term heart damage in people who take Herceptin. Continue reading

How long can I stay on Herceptin?

Treatment regimens for Herceptin vary depending on hospital protocols, but for the treatment of HER2+ early breast cancer, treatment is usually continued for one year (up to 18 cycles). Continue reading

See also:

Related medical questions

Related support groups